Chemotherapy-Free Combination of Obinutuzumab and Ibrutinib in First LINE Treatment of Follicular Lymphoma. the Alternative Study By the German Low Grade Lymphoma Study Group (GLSG)

Schmidt Christian; Zoellner Anna-Katharina; Jurinovic Vindi; Soekler Martin; Forstpointner Roswitha; Haubner Sascha; Buske Christian; Viardot Andreas; Keller Ulrich; Pott Christiane; Graeven Ullrich; Marks Reinhard; Haenel Mathias; Liersch Ruediger; Duerig Jan; Hoster Eva; Unterhalt Michael; Hiddemann Wolfgang

首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Chemotherapy-Free Combination of Obinutuzumab and Ibrutinib in First LINE Treatment of Follicular Lymphoma. the Alternative Study By the German Low Grade Lymphoma Study Group (GLSG)

【24h】

Chemotherapy-Free Combination of Obinutuzumab and Ibrutinib in First LINE Treatment of Follicular Lymphoma. the Alternative Study By the German Low Grade Lymphoma Study Group (GLSG)

机译：obinutuzumab和Ibrutinib在第一线治疗卵泡淋巴瘤的化疗组合。德国低级淋巴瘤研究组（GLSG）的替代研究

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Blood: The Journal of the American Society of Hematology》 |2018年第novaelatreatmentappr期|共4页
作者
Schmidt Christian; Zoellner Anna-Katharina; Jurinovic Vindi; Soekler Martin; Forstpointner Roswitha; Haubner Sascha; Buske Christian; Viardot Andreas; Keller Ulrich; Pott Christiane; Graeven Ullrich; Marks Reinhard; Haenel Mathias; Liersch Ruediger; Duerig Jan; Hoster Eva; Unterhalt Michael; Hiddemann Wolfgang;
展开▼
作者单位

Ludwig Maximilians Univ Munchen Univ Hosp Dept Med 3 Munich Germany;

Ludwig Maximilians Univ Munchen Univ Hosp Dept Med 3 Munich Germany;

Ludwig Maximilians Univ Munchen Univ Hosp Dept Med 3 Munich Germany;

Univ Hosp Tubingen Germany;

Ludwig Maximilians Univ Munchen Univ Hosp Dept Med 3 Munich Germany;

Ludwig Maximilians Univ Munchen Univ Hosp Dept Med 3 Munich Germany;

Comprehens Canc Ctr Ulm Inst Expt Canc Res Ulm Germany;

Univ Hosp Ulm Dept Internal Med 3 Ulm Germany;

Tech Univ Munich Klinikum Rechts Isar Munich Germany;

Univ Hosp Schleswig Holstein Kiel Germany;

Kliniken Maria Hilf GmbH Hematol Oncol &

Gastroenterol Monchengladbach Germany;

Univ Med Ctr Dept Hematol &

Oncol Freiburg Germany;

Klinikum Chemnitz Dept Internal Med 3 Chemnitz Germany;

Gemeinschaftspraxis Hamatol &

Onkol Munster Germany;

Univ Hosp Essen Essen Germany;

Ludwig Maximilians Univ Munchen Inst Med Informat Biometry &

Epidemiol Munich Germany;

Ludwig Maximilians Univ Hosp Dept Med 3 Munich Germany;

Ludwig Maximilians Univ Munchen Univ Hosp Dept Med 3 Munich Germany;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类血液及淋巴系疾病;
关键词

相似文献

外文文献
中文文献
专利

1. 复发性晚期滤泡性淋巴瘤的IDEC-C2B8(利妥希玛)抗CD20抗体治疗:德国低度恶性淋巴瘤研究组Ⅱ期研究结果 [J] . 李登举, 唐锦治中德临床肿瘤学杂志（英文版） . 2001,第004期
2. Obinutuzumab治疗中国B细胞淋巴瘤患者的安全性和有效性:GERSHWIN试验的二次分析 [J] . Yan Qin, Yuqin Song, Zhixiang Shen, 癌症（英文版） . 2019,第002期
3. 德国霍奇金淋巴瘤研究小组报告:原发性霍奇金病继发非霍奇金淋巴瘤的发病率、治疗及预后 [J] . U.Rueffer, 张玉平, 等中德临床肿瘤学杂志（英文版） . 2001,第006期
4. Chemotherapy-Free Combination of Obinutuzumab and Ibrutinib in First LINE Treatment of Follicular Lymphoma. the Alternative Study By the German Low Grade Lymphoma Study Group (GLSG) [J] . Schmidt Christian, Zoellner Anna-Katharina, Jurinovic Vindi, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：obinutuzumab和Ibrutinib在第一线治疗卵泡淋巴瘤的化疗组合。德国低级淋巴瘤研究组（GLSG）的替代研究
5. High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG). [J] . Weide R, Hess G, Koppler H, Leukemia and lymphoma . 2007,第7期

机译：苯达莫司汀/米托蒽醌/利妥昔单抗在利妥昔单抗预处理的复发性或难治性惰性淋巴瘤和套细胞淋巴瘤中具有很高的抗淋巴瘤活性。德国低级淋巴瘤研究小组（GLSG）的多中心II期研究。
6. The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG) [J] . C Buske, E Hoster, M Dreyling, Leukemia . 2009,第1期

机译：利妥昔单抗联合CHOP（R-CHOP）一线治疗可提高淋巴浆细胞性淋巴瘤患者的应答率和治疗失败时间：德国低级淋巴瘤研究小组（GLSG）的一项随机试验结果）
7. An MRM study of EZH2 and its somatic mutations in follicular and diffuse large B cell lymphoma [C] . Annie Moradian, S.-W. Grace Cheng, Damian B. Yap, American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics . 2011

机译：EZH2的MRM研究及其卵泡弥漫性大B细胞淋巴瘤
8. Transfection of cells of low-grade lymphoproliferative disorders (chronic lymphocyte leukemia and follicular lymphoma) with myc and/or ras and mutantp53. [D] . Zheng, Changyu. 1996

机译：用myc和/或ras和突变体p53转染低度淋巴细胞增生性疾病（慢性淋巴细胞性白血病和滤泡性淋巴瘤）的细胞。
9. Therapy of nodal Follicular Lymphoma (WHO grade 1/2) in clinical stage I/II using response adapted Involved Site Radiotherapy in combination with Obinutuzumab (Gazyvaro) - GAZAI Trial (GAZyvaro and response adapted Involved-site Radiotherapy): a study protocol for a single-arm non-randomized open national multi-center phase II trial [O] . Laila König, Martin Dreyling, Jan Dürig, 2019

机译：使用适应性反应的介入位点放射疗法与奥比妥单抗（Gazyvaro）组合治疗在临床I / II期淋巴结滤泡性淋巴瘤（WHO 1/2级）-GAZAI试验（GAZyvaro和适应性反应的介入位点放射疗法）：一项针对单臂非随机开放国家多中心II期临床试验
10. The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG) [O] . C Buske, E Hoster, M Dreyling, 2008

机译：将Rituximab与Chec（R-Chec）的前线疗法加入到淋巴基状淋巴瘤患者患者的响应速率和更长的治疗失败的时间：德国低级淋巴瘤研究组的随机试验结果（GLSG ）

Chemotherapy-Free Combination of Obinutuzumab and Ibrutinib in First LINE Treatment of Follicular Lymphoma. the Alternative Study By the German Low Grade Lymphoma Study Group (GLSG)

著录项

相似文献

相关主题

期刊订阅